Idiopathic hypersomnia | |
---|---|
Specialty | Sleep medicine, Neurology, Psychiatry |
Symptoms | Difficulty staying awake, mental fog, persistent sleepiness |
Idiopathic hypersomnia (IH) is a neurological disorder which is characterized primarily by excessive sleep and excessive daytime sleepiness (EDS).[1] Idiopathic hypersomnia was first described by Bedrich Roth in 1976, and it can be divided into two forms: polysymptomatic and monosymptomatic.[2][3] The condition typically becomes evident in early adulthood and most patients diagnosed with IH will have had the disorder for many years prior to their diagnosis.[4] As of August 2021[update], an FDA-approved medication exists for IH called Xywav, which is an oral solution of calcium, magnesium, potassium, and sodium oxybates;[5] in addition to several off-label treatments (primarily FDA-approved narcolepsy medications).[6]
Idiopathic hypersomnia may also be referred to as IH, IHS, or primary hypersomnia,[7] and belongs to a group of sleep disorders known as central hypersomnias, central disorders of hypersomnolence, or hypersomnia of brain origin.[8] Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) defines idiopathic hypersomnia as EDS without narcolepsy or the associated features of other sleep disorders.[9] It occurs in the absence of medical problems or sleep disruptions, such as sleep apnea, that can cause secondary hypersomnia.
fdaref
was invoked but never defined (see the help page).ref-5
was invoked but never defined (see the help page).